Skip to main content
. 2018 May;365(2):272–280. doi: 10.1124/jpet.117.247288

Fig. 4.

Fig. 4.

Liver drug concentrations in hCYP3A-NOG (hCYP3A) and NOG mice. Mice were treated intramuscularly with 20 or 50 mg/kg nanoATV/r or 50 mg/kg nanoATV on days 0, 3, 7, 14, and 21 and livers were collected on day 28. Liver ATV (A) and RTV (B) concentrations were determined by UPLC tandem MS. Data are expressed as mean ± S.E.M. *Significantly different than similarly treated NOG mice (P < 0.05). Significantly different than hCYP3A mice treated with 50 mg/kg nanoATV/r (P < 0.05).